Financial Gravity Asset Management, Inc. Editas Medicine, Inc. Transaction History

Financial Gravity Asset Management, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 08, 2023	BUY	$6.36 - $11.47 $50 - $91	8 New	8 $9,000
Q4 2022 Feb 15, 2023	BUY	$8.32 - $13.21 $74 - $118	9 New	9 $9,000
Q2 2022 Aug 05, 2022	SELL	$9.99 - $21.35 $189 - $405	-19 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$14.08 - $27.63 $112 - $221	-8 Reduced 29.63%	19 $1,000
Q4 2021 Feb 11, 2022	BUY	$26.55 - $40.57 $716 - $1,095	27 New	27 $3,000
Q3 2021 Nov 12, 2021	BUY	$39.27 - $72.94 $0 - $0	0 New	0 $41,000
Q2 2021 Aug 11, 2021	BUY	$31.29 - $56.64 $0 - $0	0 New	0 $57,000

248

57M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $87.3M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Financial Gravity Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Financial Gravity Asset Management, Inc. with notifications on news.